在费用方面，水滴公司2025年第一季度营业费用为6.78亿元人民币，同比增长3%。其中，运营成本增长较快，达到3.742亿元，同比增长13%。而销售及 市场营销费用则有所下降，为1.724亿元，同比下降5.4%。一般及行政支出也呈现下降趋势，为7490万元，同比下降15.8%。研发费用保持在5620万元的水 平。 尽管费用有所增长，但水滴公司仍实现了可观的营业利润。第一季度营业利润为7590万元，运营利润率为10.1%。公司还实现了3380万元的利息收入，所 得税费用为1330万元。 水滴公司近期发布了其截至2025年3月31日的2025年第一季度未经审计财务报告。数据显示，该季度水滴公司总营收达到7.54亿元人民币，与去年同期的 7.05亿元相比，实现了7%的增长。 在营收构成方面，保险相关收入占据主导地位，达到6.58亿元人民币，同比增长8.4%。这一增长主要得益于水滴公司在保险业务上的持续深耕和市场拓 展。服务费收入保持稳定，为6710万元，与去年第一季度基本持平。数字化临床试验解决方案收入也实现了11.5%的增长，达到2300万元。 在财务运作方面，水滴公司表现积极。自2021年9月启动股票回购计划以 ...

Group 1 - The company reported a net operating revenue of 754 million yuan for Q1 2025, representing a year-on-year growth of 7% [1] - The net profit attributable to the parent company reached 108 million yuan, with a year-on-year increase of 34.2%, marking the 13th consecutive quarter of profitability [1] - Operating expenses, including sales, management, and R&D costs, accounted for 40.3% of revenue, a decrease of 6.1 percentage points year-on-year [1] Group 2 - Insurance-related revenue for the first quarter was 658 million yuan, showing a year-on-year growth of 8.4%, with an operating profit of 151 million yuan [1] - The first-year premium for the insurance business was 2.092 billion yuan, reflecting a year-on-year increase of 19.3% [1] Group 3 - The company's crowdfunding platform, which assists patients in urgent need, has seen approximately 475 million users donate a total of 68.8 billion yuan since its launch, with a Q1 operating loss of about 30.2 million yuan [3] - The digital clinical trial solutions business generated a net operating revenue of 23 million yuan in Q1 2025, an increase of 11.5% year-on-year, with partnerships established with 185 pharmaceutical companies and contract research organizations [3] - As of the end of March, the company had completed 1,281 projects and enrolled 11,217 patients [3]